Iodine-131-labeled diphosphonates for palliative treatment of bone metastases: II. Preliminary clinical results with iodine-131 BDP3.

Abstract

The kinetics, dosimetry, and response of iodine-131 alpha-amino-(4-hydroxybenzylidene)-diphosphonate ([131I]BDP3) treatment were investigated with patients who had pain symptoms from bone metastases of various primary carcinoma. The blood clearance of [131I]BDP3 was rapid. More than 90% disappeared from the blood pool at 2 hr after injection. The excretion of the activity occurred solely through the kidneys and mean total-body retention at 48 hr was 48.6%. The urinary activity showed a metabolite which must be formed by an in vivo cleavage reaction of a phosphorus-carbon bond. The uptake of in vivo cleaved [131I]iodide in the unblocked thyroid was approximately 0.5%. The effective half-life of [131I]BDP3 in metastatic bone (median 182 hr; range 177-205 hr) proved to be longer than in unaffected areas (145 hr; 140-165 hr). Palliative therapies were performed with 18 patients. They received doses ranging between 6 and 48 mCi [131I]BDP3. The response was 44% complete pain relief, 6% substantial pain relief, 22% minimal improvement, and 28% no change. The duration of response ranged between 1 and 8 wk.

• Authors: M Eisenhut, R Berberich, B Kimmig, E Oberhausen
• Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine (J Nucl Med) Vol. 27 Issue 8 Pg. 1255-61 (Aug 1986) ISSN: 0161-5505 [Print] United States
• PMID: 2426428 (Publication Type: Journal Article)

Chemical References

• Benzylidene Compounds
• Diphosphonates
• Iodine Radioisotopes
• alpha-amino-(4-hydroxybenzylidene)diphosphonate

Topics

• Benzylidene Compounds
• Bone Neoplasms (diagnostic imaging, radiotherapy, secondary)
• Bone and Bones (diagnostic imaging, metabolism)
• Diphosphonates
• Female
• Half-Life
• Humans
• Iodine Radioisotopes (therapeutic use)
• Kinetics
• Male
• Pain Management
• Palliative Care (methods)
• Radionuclide Imaging
• Radiotherapy Dosage